



Published in final edited form as:  
*Neurogenetics*. 2004 June ; 5(2): 109–114.

## Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16

**Luc Djoussé,**

*Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, Massachusetts, USA*

**Beth Knowlton,**

*Department of Neurology, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts, MA 02118, USA*

**Michael R. Hayden,**

*Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada*

**Elisabeth W. Almqvist,**

*Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada*

**Ryan R. Brinkman,**

*Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada*

**Christopher A. Ross,**

*Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA*

**Russel L. Margolis,**

*Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA*

**Adam Rosenblatt,**

*Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA*

**Alexandra Durr,**

*Hopital de la Salpetriere, Paris, France*

**Catherine Dode,**

*Hopital de la Salpetriere, Paris, France*

**Patrick J. Morrison,**

*Department of Medical Genetics, Belfast City Hospital Trust, Belfast, UK*

**Andrea Novelletto,**

*Department of Cell Biology, University of Calabria, Rende, Italy*

**Marina Frontali,**

*Institute of Experimental Medicine, CNR, Rome, Italy*

**Ronald J. A. Trent,**

*Department of Medicine, University of Sydney, Sydney, Australia*

**Elizabeth McCusker,**

*Neurology Department, Westmead Hospital, Sydney, Australia*

**Estrella Gómez-Tortosa,**

*Servicio de Neurología y Genética, Fundación Jiménez Díaz, Madrid, Spain*

**David Mayo Cabrero,**

*Servicio de Neurología y Genética, Fundación Jiménez Díaz, Madrid, Spain*

**Randi Jones,**

*Emory Neurobehavioral Center, Atlanta, Georgia, USA*

**Andrea Zanko,**

*UCSF Division of Medical Genetics, San Francisco, California, USA*

**Martha Nance,**

*Department of Neurology, Hennepin County Medical Center, Minneapolis, Minnesota, USA*

**Ruth K. Abramson,**

*Department of Neuropsychiatry and Behavior, WMS Hall Psychiatric Institute, Columbia, South Carolina, USA*

**Oksana Suchowersky,**

*Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada*

**Jane S. Paulsen,**

*Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA*

**Madaline B. Harrison,**

*Department of Neurology, University of Virginia, Charlottesville, Virginia, USA*

**Qiong Yang,**

*Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA*

**L. Adrienne Cupples,**

*Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA*

**Jayalakshmi Mysore,**

*Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA*

**James F. Gusella,**

*Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA*

**Marcy E. MacDonald, and**

*Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA*

**Richard H. Myers**

*Evans Department of Medicine, Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, Massachusetts, USA, Department of Neurology, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts, MA 02118, USA, e-mail: rmyers@bu.edu, Tel.: +1-617-6385376, Fax: +1-617-6388076*

**Abstract**

Huntington disease (HD) is a neurodegenerative disorder caused by the abnormal expansion of CAG repeats in the *HD* gene on chromosome 4p16.3. A recent genome scan for genetic modifiers of age at onset of motor symptoms (AO) in HD suggests that one modifier may reside in the region close to the *HD* gene itself. We used data from 535 HD participants of the New England Huntington cohort

and the HD MAPS cohort to assess whether AO was influenced by any of the three markers in the 4p16 region: *MSX1* (*Drosophila* homeo box homologue 1, formerly known as homeo box 7, *HOX7*),  $\Delta 2642$  (within the *HD* coding sequence), and *BJ56* (*D4S127*). Suggestive evidence for an association was seen between *MSX1* alleles and AO, after adjustment for normal CAG repeat, expanded repeat, and their product term (model *P* value 0.079). Of the variance of AO that was not accounted for by HD and normal CAG repeats, 0.8% could be attributed to the *MSX1* genotype. Individuals with *MSX1* genotype 3/3 tended to have younger AO. No association was found between  $\Delta 2642$  (*P*=0.44) and *BJ56* (*P*=0.73) and AO. This study supports previous studies suggesting that there may be a significant genetic modifier for AO in HD in the 4p16 region. Furthermore, the modifier may be present on both HD and normal chromosomes bearing the 3 allele of the *MSX1* marker.

## Keywords

Huntington disease; Modifier; Onset age; Genetics; Trinucleotide repeat; HD gene

## Introduction

Huntington disease (HD) is a neurodegenerative disorder with complex clinical features [1,2,3,4]. The genetic mutation associated with HD is located on 4p16.3 [5] and is characterized by CAG trinucleotide expansion [6].

It has been demonstrated that age at motor onset (AO) is inversely related to the size of expanded CAG repeat [7,8,9,10], but little is known about other genetic modifiers (subsequently referred to as modifiers) of AO among HD-affected persons. Farrer et al. [11] were the first to suggest that HD expression may be modulated by a gene close to the *HD* locus. A recent genome scan for AO modifiers reported evidence for linkage to the *HD* locus [12].  $\Delta 2462$  is an intragenic deletion of a codon in the *HD* gene area [13] and *BJ56* (start to stop 3,084,110 to 3,084,274 bp)—also known as *D4S127* [14]—is a dinucleotide repeat located 23.4 kb 5' of the *HD* gene. The *MSX1* gene [15] (start to stop 4,925,948 to 4,930,000) is located 1.6 Mb proximal and 3' to the *HD* gene. Given the proximity of these markers to the *HD* gene and a recent genome scan for AO modifiers showing linkage to the *HD* locus, we used information from 535 HD affected persons to test whether polymorphisms in the *MSX1* gene,  $\Delta 2642$ , or *BJ56* markers may explain variation in AO, after adjustment for normal, expanded CAG repeats and the interaction of these two as defined by their product term [16].

## Patients and methods

### Patients

Data were collected on 221 participants from the New England Huntington Disease Center (parent-offspring pairs referred to as HD PAIRS) and 533 participants of the Huntington Disease, Modifiers in Age at onset in Pairs of Sibs (HD MAPS study). Over 95% of these participants were Caucasian. Of these subjects, 535 had complete data on AO and CAG repeat sizes. However, limited subjects had genotype data on *MSX1* (*n*=192),  $\Delta 2642$  (*n*=518), or *BJ56* (*n*=471). Of the 535 subjects, 480 were from the HD MAPS study and 55 were from unaffected parent-affected offspring HD PAIRS described earlier [17]. DNA samples in the HD MAPS were collected mainly for the purpose of genome scan. Thus, the sample size of subjects genotyped for *MSX1*, *BJ56*, and  $\Delta 2642$  was mainly driven by the amount of available DNA. We did not have enough DNA to analyze all three genes/markers in each subject. The fewer genotypes for *MSX1* were not a consequence of increased error rate, but that fewer samples could be typed.

For the HD PAIRS, the normal chromosomes were determined by the alleles transmitted by the unaffected parent and HD chromosomes as those not transmitted by the unaffected parent. For the HD MAPS, the HD and normal chromosomes were determined by the allele sharing of siblings, assuming that all affected siblings shared their HD chromosomes. In this sample this assumption is very likely true in all cases as the gene frequency for HD is very low. AO was defined as the onset of motor impairment [18,19,20]. For *MSX1*, *BJ56*, and  $\Delta 2642$ , there were no differences in allele frequencies for the New England versus all other samples.

### CAG repeat size determination

CAG repeat sizes were determined by polymerase chain reaction of the number of CAG trinucleotide repeats responsible for the *HD* gene [6], using a modified protocol that eliminated an adjacent proline (CCG) repeat [21,22]. Cases with 36 or more repeats were designated HD gene carriers, in accordance with published associations with disease expression [23].

### Marker determination: *MSX1*, $\Delta 2642$ , and *BJ56*

The *MSX1* dinucleotide repeat was typed using a forward primer: TTAGATTGTCTCAGTCCTC, and a reverse primer: GGGCAT-GTTGATGCTGCTGAC. This dinucleotide repeat polymorphism has four alleles of 169, 171, 173, and 175 bp length. In the subsequent text, these alleles are referred to as 1 through 4, respectively.

The  $\Delta 2642$  polymorphism is a deletion of one of four consecutive GAG codons (Glu) at positions 2642–2645 [13]. The deletion (B allele) is found in about 7% of the general population and 38% of HD chromosomes. The  $\Delta 2642$  was assayed as previously described [13].

The *BJ56* (*D4S127*) polymorphism is located at 40 kb 5' to the transcription initiation site for the *HD* gene. The polymorphism is a dinucleotide repeat with five alleles of 157, 155, 153, 151, and 149 bp length (referred to in text simply as 2, 4, 6, 8, and 10, respectively). The assay for *D4S127* was performed as previously described [14].

Of the 535 affected people with genotype data on at least one of the three genes/markers, the phase for *MSX1* could be established in 139 subjects. For  $\Delta 2642$  and *BJ56*, the phase was established in 286 and 260 subjects, respectively.

### Statistical analysis

We initially conducted analyses within each cohort, HD MAPS and the HD PAIRS sample, separately. Since the results were similar within each cohort, we pooled the data. To evaluate the association between each marker and AO, we created residuals of AO by regressing AO on normal repeats, expanded repeats, and their product term. We used the natural logarithm to transform AO as this has been shown to provide the best linear relation of repeat size to onset age [7,9,10]. For each marker, we determined individual genotypes (referred to as “genotype only”). In addition, we determined genotypes along with the location of a particular allele on the normal or affected chromosome (referred to as “genotype and phase”). We were not able to set phase for all subjects. For example, when the parent and offspring were both heterozygous for the same alleles at a locus, we could not tell which alleles were transmitted from the parent. We used a generalized linear model (*Proc Mixed* in SAS) to compare mean residuals of AO among different genotypes (genotype only, genotype and phase). This method accommodates the familial correlation between subjects. The significance level was set at 0.05 and all analyses were performed using SAS for windows, release 8.02, and version 5.1.

## Results

Among the 535 HD subjects, the mean AO was  $38.3 \pm 12.1$  years (range 8–78 years). The expanded CAG repeat ranged from 36 to 80 (mean  $\pm$  SD  $46.7 \pm 6.0$ ) and the unexpanded repeat (normal allele) size ranged from 6 to 33 (mean  $\pm$  SD  $18.8 \pm 3.5$ ). Complete data were available on 192 subjects genotyped for *MSX1*. For  $\Delta 2642$  and *BJ56*, corresponding numbers were 518 and 471, respectively. We observed suggestive evidence for an association between *MSX1* and AO after controlling for normal, expanded CAG repeats, and their interaction (global *P* value for the model 0.079 for all subjects with genotype data on *MSX1* and 0.06 when restricted to subjects with known phase, Table 1). Only subjects with 3/3 genotype tended to have less than expected AO ( $P < 0.05$ ). We also noted that those with the 3/4 genotypes had the same mean level as the 3/3 group, but this effect was not statistically significant, perhaps due to the smaller sample size. A post hoc analysis assessing the presence of allele 3 (versus absence of allele 3) showed that the presence of allele 3 was associated with a significant younger than expected AO [beta coefficient  $-0.4424$  (SE 0.1464),  $P = 0.013$ ]. The adjusted mean residuals of AO were  $-0.2743$  (SE 0.116) for subjects with allele 3 and 0.1681 (SE 0.089) for people without allele 3. This means that subjects with allele 3 have an AO that is  $\sim 5.4$  years earlier than subjects without allele 3.

In the analysis restricted to subjects with established phase, there was a borderline significant association between *MSX1* and AO (model  $P = 0.06$ , Table 1). About 0.8% of the residual variance of AO (after adjustment for normal CAG repeat, expanded CAG repeat, and their product term) could be explained by *MSX1* polymorphism. Neither  $\Delta 2642$  nor *BJ56* was associated with AO (Tables 2 and 3).

## Discussion

HD is an autosomal dominant disease characterized by neurological and psychiatric symptoms. The *HD* gene is a trinucleotide repeat expansion and the size of the repeat is known to be associated with AO for HD. Several studies have shown that AO is inversely related to the size of CAG repeat. In addition, the *GRIK2* (ionotropic glutamate receptor, kainite 2 subunit; formerly *GLUR6*) gene has been found to explain about 13% of the remaining variance of AO after adjustment for CAG repeats [24], with a particular allele being associated with a younger AO [25]. However, a large portion of the variation of AO remains unexplained after controlling for repeat sizes and their interaction [16]. It has been suggested that other genes on chromosome 4 might interact with the *HD* gene to modify the AO of HD [11]. A recent genome scan for AO modifiers in HD suggests that there may be an AO modifier in the region of the *HD* gene [12].

In the present study, we assessed whether *MSX1*,  $\Delta 2642$ , and *BJ56*—since these markers are close to *HD* gene—were associated with the AO of HD. Our findings are suggestive of an association between *MSX1* and AO. Individuals with *MSX1* genotype 3/3 appear to have earlier AO than expected from their CAG repeat lengths, with a mean residual of AO of  $-0.61$ ; this means that their HD age at onset is about 7.5 years earlier than expected. Neither  $\Delta 2642$  nor *BJ56* was associated with AO in this population.

This is the first study to examine whether a gene in the *MSX1* region modifies AO in HD. Although a distance of  $\sim 1.5$  Mb separates the *HD* and *MSX1* genes, these genes may interact through their end products to influence AO, although the biological mechanism remains unclear at present. Data from mouse/human hybrid cell lines indicate that *MSX1* maps to human chromosome 4p16.1 [15]. Genes containing the homeo box 183-bp DNA sequence [26] are thought to control segmentation in *Drosophila* [27,28]. However, the role of *MSX1* in humans is not well established [29]. *MSX1* mutations have been associated with tooth and nail disorders

in humans [30,31]. It is perhaps more likely that the observed effect on AO might be attributable to another gene in disequilibrium with the *MSX1* polymorphism. These results are supported by evidence of linkage in the *HD* region in a recent genome scan using the same data set [12].

While  $\Delta 2642$  is intragenic and *BJ56* is very close to the *HD* gene, we did not find evidence for modification of AO by either of these markers. The B allele of  $\Delta 2642$  has been associated with a higher CAG repeat size on the normal chromosome [32]. Our null findings for  $\Delta 2642$  are consistent with the report of Novelletto et al. [33], who did not find an association between  $\Delta 2642$  and AO. In contrast, among French families, subjects with  $\Delta 2642$  deletion (allele B) had an increased CAG size and had a younger AO (about 4 years earlier) than HD subjects without  $\Delta 2642$  deletion [34]. We do not have a reasonable explanation for the discrepancy among these reports. Contrary to our study, both earlier studies did not adjust for the CAG repeat sizes when assessing the effects of  $\Delta 2642$  on AO. We do not know whether after correcting for CAG lengths in the French study [34],  $\Delta 2642$  deletion would have been associated with younger AO.

In conclusion, our study supports the hypothesis that there is a modifier of AO in the general region of *HD* and this modifier may be close to the *MSX1* gene. Study of genes close to the *MSX1* polymorphism may be important to identify the specific modifier of AO among HD patients.

#### Acknowledgements

This study was supported by PHS grant P50NS016367 (Huntington Disease Center Without Walls), and by grants from the Massachusetts Huntington Disease Society of America, the Coalition for the Cure of HDSA, and the Jerry McDonald Huntington's Disease Research Fund.

#### References

1. Huntington G. On chorea. *Med Surg Rep* 1872;26:320–321.
2. Hayden MR, Berkowicz AL, Beighton PH, Yiptong C. Huntington's chorea on the island of Mauritius. *S Afr Med J* 1981;60:1001–1002. [PubMed: 6460324]
3. Folstein, SE. Huntington's disease: a disorder of families. The Johns Hopkins University Press; Baltimore: 1989.
4. White, RF.; Vasterling, JJ.; Koroshetz, W.; Myers, RH. Neuropsychology of Huntington's disease. In: White, RF., editor. *Clinical syndromes in adult neuropsychology: the practioners handbook*. Elsevier; New York: 1992. p. 213-251.
5. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB. A polymorphic DNA marker genetically linked to Huntington's disease. *Nature* 1983;306:234–238. [PubMed: 6316146]
6. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993;79:971–983.
7. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, Gray J, Conneally P, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini A, Falek A, Koroshetz W, Sax D, Bird E, Vonsattel J, Bonilla E, Alvir J, Conde JB, Cha JH, Dure L, Gomez F, Ramos M, Sanchezramos J, Snodgrass S, Deyoung M, Wexler N, Moscowitz C, Penchaszadeh G, Macfarlane H, Anderson M, Jenkins B, Srinidhi J, Barnes G, Gusella J, Macdonald M. Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nat Genet* 1993;4:387–392. [PubMed: 8401587]
8. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. *Nat Genet* 1993;4:393–397. [PubMed: 8401588]
9. Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML, Chao NI, Chung AS, Pleasant N, Callahan C, Kasch LM, Ghaffari M, Chase GA, Kazazian HH, Brandt J, Folstein SE, Ross CA.



Anticipation and instability of IT-15 (CAG)<sub>n</sub> repeats in parent-offspring pairs with Huntington disease. *Am J Hum Genet* 1995;57:593–602. [PubMed: 7668287]

10. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. *Am J Hum Genet* 1997;60:1202–1210. [PubMed: 9150168]
11. Farrer LA, Cupples LA, Wiater P, Conneally PM, Gusella JF, Myers RH. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. *Am J Hum Genet* 1993;53:125–130. [PubMed: 8317477]
12. Li J, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, Morrison PJ, Sudo H, Ross CA, Margolis RL, Rosenblatt A, Gomez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, Nance M, Trent RJ, McCusker E, Jones R, Paulsen JS, Harrison M, Zanko A, Abramson RK, Russ AL, Djousse L, Mysore JS, Tariot S, Gusella MF, Wheeler VC, Atwood LD, Cupples LA, Saint-Hilaire M, Cha JH, Hersch SM, Koroshetz WJ, Gusella JF, MacDonald ME, Myers RH. A genome scan for modifiers of age at onset in Huntington's disease: The HD MAPS Study. *Am J Hum Genet* 2003;73:682–687. [PubMed: 12900792]
13. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, Gusella J, Macdonald ME. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. *Somat Cell Mol Genet* 1994;20:27–38. [PubMed: 8197474]
14. Taylor SA, Barnes GT, MacDonald ME, Gusella JF. A dinucleotide repeat polymorphism at the D4S127 locus. *Hum Mol Genet* 1992;1:142. [PubMed: 1339471]
15. Ivens A, Flavin N, Williamson R, Dixon M, Bates G, Buckingham M, Robert B. The human homeobox gene *HOX7* maps to chromosome 4p16.1 and may be implicated in Wolf-Hirschhorn syndrome. *Hum Genet* 1990;84:473–476. [PubMed: 1969845]
16. Djousse L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, Margolis R, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, Gomez-Tortosa E, Mayo D, Jones R, Zanko A, Nance M, Abramson R, Suchowersky O, Paulsen J, Harrison M, Yang Q, Cupples LA, Gusella JF, MacDonald ME, Myers RH. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. *Am J Med Genet* 2003;119A:279–282.
17. MacDonald ME, Novelletto A, Lin C, Tagle D, Barnes G, Bates G, Taylor S, Allitto B, Altherr M, Myers R, Lehrach H, Collins FS, Wasmuth JJ, Frontali M, Gusella JF. The Huntington's disease candidate region exhibits many different haplotypes. *Nat Genet* 1992;1:99–103. [PubMed: 1302016]
18. Myers RH, Madden JJ, Teague JL, Falek A. Factors related to onset age of Huntington disease. *Am J Hum Genet* 1982;34:481–488. [PubMed: 6211092]
19. Conneally PM. Huntington disease: genetics and epidemiology. *Am J Hum Genet* 1984;36:506–526. [PubMed: 6233902]
20. Farrer LA, Conneally PM. Predictability of phenotype in Huntington's disease. *Arch Neurol* 1987;44:109–113. [PubMed: 2948483]
21. Barron LH, Warner JP, Porteous M, Holloway S, Simpson S, Davidson R, Brock DJ. A study of the Huntington's disease associated trinucleotide repeat in the Scottish population. *J Med Genet* 1993;30:1003–1007. [PubMed: 8133495]
22. Zuhlke C, Riess O, Schroder K, Siedlaczek I, Epplen JT, Engel W, Thies U. Expansion of the (CAG)<sub>n</sub> repeat causing Huntington's disease in 352 patients of German origin. *Hum Mol Genet* 1993;2:1467–1469. [PubMed: 8242072]
23. Myers, RH.; Marans, K.; MacDonald, ME. Huntington's disease. In: Warren, ST.; Wells, RT., editors. Genetic instabilities and hereditary neurological diseases. Academic Press; 1998. p. 301-323.
24. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, Craufurd D. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. *Proc Natl Acad Sci USA* 1997;94:3872–3876. [PubMed: 9108071]
25. MacDonald ME, Vonsattel JP, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED, Gusella JF, Myers RH. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. *Neurology* 1999;53:1330–1332. [PubMed: 10522893]

26. Hewitt JE, Clark LN, Ivens A, Williamson R. Structure and sequence of the human homeobox gene *HOX7*. *Genomics* 1991;11:670–678. [PubMed: 1685479]
27. Ingham PW. The molecular genetics of embryonic pattern formation in *Drosophila*. *Nature* 1988;335:25–34. [PubMed: 2901040]
28. Gehring WJ. Homeo boxes in the study of development. *Science* 1987;236:1245–1252. [PubMed: 2884726]
29. Slack JM. Homoeotic transformations in man: implications for the mechanism of embryonic development and for the organization of epithelia. *J Theor Biol* 1985;114:463–490. [PubMed: 3927066]
30. Jumlongras D, Bei M, Stimson JM, Wang WF, DePalma SR, Seidman CE, Felbor U, Maas R, Seidman JG, Olsen BR. A nonsense mutation in *MSX1* causes Witkop syndrome. *Am J Hum Genet* 2001;69:67–74. [PubMed: 11369996]
31. Lidral AC, Reising BC. The role of *MSX1* in human tooth agenesis. *J Dent Res* 2002;81:274–278. [PubMed: 12097313]
32. Almqvist E, Spence N, Nichol K, Andrew SE, Vesa J, Peltonen L, Anvret M, Goto J, Kanazawa I, Goldberg YP, Hayden MR. Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. *Hum Mol Genet* 1995;4:207–214. [PubMed: 7757069]
33. Novelletto A, Persichetti F, Sabbadini G, Mandich P, Bellone E, Ajmar F, Squitieri F, Campanella G, Bozza A, MacDonald ME, Gusella JF, Frontali M. Polymorphism analysis of the huntingtin gene in Italian families affected with Huntington disease. *Hum Mol Genet* 1994;3:1129–1132. [PubMed: 7981682]
34. Lucotte G, Gerard N, Roubertoux P, Schmitt I, Riess O. Relationships of the 2642 deletion polymorphism (delta 2642) in the huntingtin gene with the CAG repeat expansion length and age at onset of the disease. *Genet Couns* 1996;7:297–302. [PubMed: 8985734]



**Table 1**

Relation between *MSX1* and unexplained variance of age at onset (AO) of Huntington disease (HD) among HD subjects from the HD MAPS and HD PAIRS data sets<sup>a</sup>

		<i>n</i>	Mean residual of AO±SE
By genotype only ( <i>n</i> =192)			
1/1		70	0.12±0.12
1/2		13	0.48±0.27
1/3		46	-0.17±0.14
1/4		28	0.07±0.19
2/3		5	0.26±0.44
2/4		5	0.64±0.44
3/3		15	-0.63±0.25†
3/4		6	-0.63±0.40
4/4		4	-0.21±0.49
Model <i>P</i> value			0.079
By genotype and phase ( <i>n</i> =139) <sup>b</sup>			
Normal chromosome	Affected chromosome		
1	1	67	0.10±0.12
1	2	4	0.32±0.48
1	3	9	-0.27±0.32
1	4	4	1.10±0.48*
2	1	9	0.50±0.32
3	1	11	-0.13±0.29
3	3	15	-0.61±0.25*
3	4	2	-1.62±0.68*
4	1	10	0.18±0.31
4	3	4	-0.26±0.48
4	4	4	-0.17±0.48
Model <i>P</i> value	0.06		

\* Statistically different from zero at 0.05 level

<sup>a</sup> Residuals of AO adjusted for unexpanded and expanded CAG repeats and their product term

<sup>b</sup> Among 139 subjects with known phase

**Table 2**

Relationship between  $\Delta 2642$  and unexplained variance of AO of HD in HD subjects from the HD MAPS and HD PAIRS data sets<sup>a</sup>

		<i>n</i>	Mean residual of AO±SE
By genotype only ( <i>n</i> =518)			
A/A		275	-0.05±0.06
A/B		230	0.06±0.07
B/B		13	-0.14±0.28
Model <i>P</i> value			0.44
By genotype and phase ( <i>n</i> =286) <sup>b</sup>			
Normal chromosome			
A	Affected chromosome		
A	A	251	0.02±0.06
A	B	10	-0.08±0.32
B	A	13	-0.19±0.28
B	B	12	-0.15±0.29
Model <i>P</i> value			0.82

<sup>a</sup>Residuals of AO adjusted for unexpanded and expanded CAG repeats and their product term

<sup>b</sup>Among 286 subjects with known phase

**Table 3**

Relationship between *BJ56* and unexplained variance of AO of HD in HD subjects from the HD MAPS and HD PAIRS data sets<sup>a</sup>

		<i>n</i>	Mean residual of AO±SE
By genotype ( <i>n</i> =471)			
2/2		31	-0.14±0.18
2/4		27	0.12±0.19
2/6		54	-0.27±0.14
2/8		128	0.008±0.09
2/10		4	0.003±0.50
4/4		3	0.43±0.58
4/6		28	0.07±0.19
4/8		60	-0.05±0.13
4/10		3	0.006±0.58
6/6		12	0.29±0.29
6/8		64	0.18±0.13
6/10		3	-0.25±0.58
8/8		50	0.04±0.14
8/10		4	-0.28±0.50
Model <i>P</i> value			0.73
By genotype and phase ( <i>n</i> =260) <sup>b</sup>			
Normal chromosome	Affected chromosome		
2	2	31	-0.09±0.18
2	4	4	-0.45±0.50
2	6	21	-0.22±0.22
2	8	46	-0.09±0.15
2	10	2	0.27±0.71
4	2	3	-0.73±0.58
4	4	2	0.59±0.71
4	6	15	0.02±0.26
4	8	25	0.08±0.20
6	2	4	-0.84±0.50
6	4	2	-0.55±0.71
6	6	11	0.37±0.30
6	8	21	0.21±0.22
8	2	10	0.89±0.32
8	6	13	-0.15±0.28
8	8	45	0.06±0.15
10	2	2	-0.12±0.71
10	8	3	-0.37±0.58
Model <i>P</i> value			0.33

<sup>a</sup>Residuals of AO adjusted for unexpanded and expanded CAG repeats and their product term

<sup>b</sup>Among 260 subjects with known phase